Labcorp Holdings Inc. (LH) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-24

How it makes money

Labcorp earns revenue by performing diagnostic tests and providing drug development laboratory services to patients, physicians, hospitals, and biopharmaceutical companies.

Patients, managed care organizations, and government programs pay for diagnostic testing through third-party billing, while pharmaceutical and biotechnology firms fund clinical trial and research services. Total revenues reached $13,951.7 million in 2025, driven by diagnostic testing and biopharmaceutical laboratory services. Profitability moves primarily with testing volume, price and mix changes, and operational efficiencies that absorb costs of revenues.

What protects it: the moat

Management claims that global scale, scientific strength, and differentiated specialty testing capabilities differentiate the business and power its success.

The company relies on its national presence, data and analytics capabilities, and track record of integrating laboratory services to maintain its competitive position. Management points to collaboration transactions with health systems and specialized test portfolios in oncology, women's health, autoimmune disease, and neurology as key differentiators, though it also faces intense competition for skilled laboratory and patient-facing personnel.

What growth costs

The company reinvests through capital expenditures, research and development, acquisitions, and restructuring charges to expand its specialty and consumer-centric testing capabilities.

Maintaining and growing operations requires ongoing investments in laboratory capacity, such as expanding the cell and gene therapy laboratory in Madison, Wisconsin, and modernizing patient service centers. In 2025, the company incurred $127.2 million in restructuring and other charges, $280.0 million in amortization of intangibles and other assets, and $2,216.3 million in selling, general, and administrative expenses.

What could damage it

Shifts in healthcare reimbursement models or reductions in government payment rates could permanently impair earnings by lowering test prices and collections.

If third-party payers and government programs continuously tighten payment policies and reduce reimbursement rates, and the company fails to offset those cuts through cost efficiencies or higher volumes, its revenues and cash flows would suffer a sustained negative impact.

About Labcorp Holdings Inc.

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

More on LH

Other companies in Diagnostics & Research